What you need to know The prevalence of heart failure across Europe is estimated to be 1-2% of adults.1 In the UK, this places a substantial burden on patients and healthcare resources, including ...

Dr. Hare answers the question: 'Must I Repeat Ejection Fraction Tests?' — -- Question: Should the ejection fraction test be repeated at each visit to my doctor, or at all? Answer: The ejection ...

Background Pharmacotherapy combinations have been shown to improve survival and reduce hospitalisations in adults with ...

A secondary analysis of the SOUL trial shows significant improvement in heart failure outcomes with oral semaglutide vs placebo, consistent with the injectable formulation.

An international team of researchers has discovered a natural mechanism that protects the heart from heart failure with preserved ejection fraction (HFpEF), a serious condition in need of effective ...

Adjusted analyses associated overestimation with nearly doubled 2-year mortality (aHR 1.98; 95% CI, 1.04-3.77). Differences in advanced-therapy receipt did not explain the mortality signal, suggesting ...

MRI results highlighted that patients with baseline cardiomyopathy saw a 3.3 percentage-point improvement in left ventricular ejection fraction. ・Capricor has already submitted a BLA for Deramiocel to ...

Respiratory sarcopenia, defined by low diaphragm thickness and reduced FVC, is associated with increased 2-year mortality in HF.

Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure that affects the left side of the heart. It occurs when the lower left chamber of the heart, called the left ventricle ...